JP Morgan Chase
SGP

JP Morgan Chase’s SpyGlass Pharma SGP Stock Holding History

JP Morgan Chase’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.6M Buy
629,739
+52,630
+9% +$1.14M ﹤0.01% 2537
2026
Q1 		$13.5M Buy
+577,109
New +$15.5M ﹤0.01% 2414

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

JP Morgan Chase's SGP Position: Q2 2026 in Review

JP Morgan Chase increased its SpyGlass Pharma (SGP) stake by 9.1% in Q2 2026, buying an estimated $1.14M and bringing the position to 629,739 shares worth $13.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2537.

JP Morgan Chase first reported a position in SGP in Q1 2026 and has held it in 2 quarters since. 52 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • JP Morgan Chase held 629,739 shares of SpyGlass Pharma worth $13.6M as of Q2 2026.
  • JP Morgan Chase bought 52,630 SpyGlass Pharma shares in Q2 2026, an estimated $1.14M.
  • SpyGlass Pharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2537 holding.
  • JP Morgan Chase first reported a position in SpyGlass Pharma in Q1 2026 and has held it in 2 quarters since.
  • 52 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.